Lantheus Holdings, Inc. (LNTH) News
Filter LNTH News Items
LNTH News Results
|Loading, please wait...|
LNTH News Highlights
- For LNTH, its 30 day story count is now at 15.
- Over the past 28 days, the trend for LNTH's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ABR, BEAT and EYE are the most mentioned tickers in articles about LNTH.
Latest LNTH News From Around the Web
Below are the latest news stories about LANTHEUS HOLDINGS INC that investors may wish to consider to help them evaluate LNTH as an investment opportunity.
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Zacks.com users have recently been watching Lantheus Holdings (LNTH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m. GMT (3 a.m. EST) on Wednesday, November 15. To access a live webcast of
Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Lantheus Holdings fair value estimate is US$82.17 Current...
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good morning. Welcome to the Lantheus Third Quarter 2023 Financial Results Conference Call. This is your operator for today’s call. Please note that all lines have been placed in mute to prevent any background noise. This call is being recorded for replay […]
Although the revenue and EPS for Lantheus Holdings (LNTH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Strong performance driven by significant growth in radiopharmaceutical oncology and precision diagnostics segments
Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year periodGAAP net income of $132.0 million for the third quarter 2023, compared to GAAP net income of $61.2 million in the prior year periodGAAP fully diluted net income per share of $1.88 for the third quarter 2023, compared to GAAP fully diluted net income per share of $0.86 in the prior year period; adjusted fully diluted net income per share of $1.47 for the third quarter 2023,
Lantheus' (LNTH) third-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.